MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
13.13
+0.02
+0.15%
After Hours: 13.13 0 0.00% 16:10 02/12 EST
OPEN
13.10
PREV CLOSE
13.11
HIGH
13.48
LOW
13.02
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
41.06
52 WEEK LOW
12.12
MARKET CAP
789.74M
P/E (TTM)
-7.8388
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JANX last week (0202-0206)?
Weekly Report · 3d ago
Vir Biotechnology: The Low-Down On The Readouts Ahead
Seeking Alpha · 6d ago
Janux Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer William Go
Reuters · 02/05 01:00
Weekly Report: what happened at JANX last week (0126-0130)?
Weekly Report · 02/02 10:04
Janux Therapeutics CMO Zachariah McIver to depart, William Go to succeed
TipRanks · 01/26 12:11
Janux Therapeutics Names William Go as Chief Medical Officer
Reuters · 01/26 12:01
JANUX THERAPEUTICS APPOINTS WILLIAM GO, M.D., PH.D., AS CHIEF MEDICAL OFFICER
Reuters · 01/26 12:00
Weekly Report: what happened at JANX last week (0119-0123)?
Weekly Report · 01/26 10:04
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.